

350
300
250
200
150
100
50
0
Relative Tumor Area
WK0
WK1
WK2
WK3
WK4
Time after start of treatment (weeks)
L back T1
L back T2
R back T
Up BK T1
Low BK T2
L ear T
Back T
ear back T
Up bk T1
Up bk T2
Up bk T3
Lt eye T
Up bk T
Lt Mid tu
Lt leg Tu

FIG. 1A



120
100
80
60
40
20
0
Relative Tumor Area
WK0
WK1
WK2
WK3
WK4
Time after start of treatment (weeks)
Up BK
Low BK
FaceT1 (close to R eye)
Face T2 (middle)
Face T3 (close to mouth)
L mouth T
Behind ear L T
Behind ear R T
BK T (two tiny)
R Back T
L Ear T
R Ear T
Up BK T1
Mid BK T2
Low BK T3
Low Lt bk T
Ear back T
ear/head Tu
ear/neck Tu
ear inside T

FIG. 1B



200
175
150
125
100
75
50
25
0
Relative Tumor Area
0
1
2
3
4
Time after start of treatment (weeks)
15 tumors CTRL Average
20 tumors compound 1* Average

FIG. 1C



200
175
150
125
100
75
50
25
0
Relative Tumor Area
0
1
2
3
4
Time after start of treatment (weeks)
15 tumors CTRL Average
20 tumors compound 1* Average

FIG. 1D



TKL
TK
STE
CK1
OTHER
AGC
CMGC
CAMK
Percent Control
0%
0.1%
0.1-1%
1-5%
5-10%
10-35%
> 35%
ATYPICAL
A6
ABC1
Alpha
BRD
PDHK
PIKK
RIO
TAF
TIF1
LIPID
Class I PI3K
Class II PI3K
Class III PI3K
Type III PI4K
Type II PI4K
Type I PIP5K
Type II PIP5K
Type III PIP5K
PATHOGEN
MUTANT
ABL1
ALK
BRAF
EGFR
FGFR3
FLT3
KIT
LRRK2
MET
PIK3CA
RET

FIG: 2



100000
10000
1000
100
10
1
Tissue conc. [ng/g]
0
6
12
18
24
Time [h]
Compound1* pH3
Compound1* pH7
Imiquimod
Compound8 pH3
Compound3 pH 3
Comound13 pH 3
Compound21 pH 3
Compound42 pH 3
Compound2* pH 3
Compound20 pH 3

FIG. 3



Tape-stripped pig skin
100000
10000
1000
100
10
ng/g tissue
0
4
8
12
16
20
24
28
Time [h]
Formulation 1: Compound1*.HCl 1%
Formulation 2: Compound1*.HCl 1%
Formulation 3: Compound3.HCl 1%
Formulation 4: Imiquimod 5%

FIG. 4



13000
11000
9000
7000
5000
3000
1000
-1000
Skin concentration (ng/g)
0
3
6
9
12
Time (h)
Compound1* @ 11.3 mg topical (F1: PG + TH)
Compound1* @ 11.3 mg topical (F3: PEG)
Compound3 @ 10.8 mg topical (F2: PG + TH)
Imiquimod

FIG. 5



Day 0
Day 3
Day 7
Day 10
Day 14
Day 17
Day 21
Day 24
1-1
NT
1-4
2-3
V
2-6
3-4
Cpd1*
3-6

FIG. 6A



End treatment at Day 24
NT
Mouse 1-1
V
Mouse 2-3
Cpd1*
Mouse 3-5
Left flank
Mid dorsal
Right flank

FIG. 6B



Day
NT Mouse 1-
NT Mouse 1-
NT Mouse 1-
Vehicle Mouse 2-
Vehicle Mouse 2-
Vehicle Mouse 2-
Cpd1* Mouse 3-
Cpd1* Mouse 3-
Cpd1* Mouse 3-
Left
Mid
Right
Non
Vehicle
Cpd1*

FIG. 7